Skip to main content


Potential Treatment for Bacterial Infections


Bacteriophages (phages) are viruses of bacteria that can kill and lyse the bacteria they infect. After their discovery early in the 20th century, phages were widely used to treat various bacterial diseases in people and animals. After this enthusiastic beginning to phage therapy, problems with inappropriate use and uncontrolled studies and ultimately the development of antibacterials caused a cessation of phage therapy research in the West. However, a few institutions in Eastern Europe continued to study and use phages as therapeutic agents for human infections. The alarming rise in antibacterial resistance among bacteria has led to a review of the Eastern European studies and to the initiation of controlled experiments in animal models. These recent studies have confirmed that phages can be highly effective in treating many different types of bacterial infections. The lethality and specificity of phages for particular bacteria, the ability of phages to replicate within infected animal hosts, and the safety of phages make them efficacious antibacterial agents. Although there are still several hurdles to be overcome, it appears likely that phage therapy will regain a role in both medical and veterinary treatment of infectious diseases, especially in the scenario of emerging antibacterial resistance.

This is a preview of subscription content, access via your institution.


  1. Tradenames are for identification purposes only and do not imply endorsement.


  1. d’Herelle F. Sur un microbe invisible antagoniste de bacilles dysenteriques. C R Acad Sci (Paris) 1917; 165: 373–5

    Google Scholar 

  2. d’Herelle F. The bacteriophage and its behavior. Baltimore: Williams and Wilkins, 1926

    Book  Google Scholar 

  3. Duckworth DH. Bacteriophages. In Granoff A, Webster RG, editors. Encyclopedia of virology. 2nd ed. San Diego (CA): Academic Press, 1999: 725–30

    Chapter  Google Scholar 

  4. Eaton MD, Bayne-Jones S. Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 1934; 23: 1769–939

    Article  Google Scholar 

  5. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45(3): 649–59

    PubMed  Article  CAS  Google Scholar 

  6. Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz) 1987; 35: 569–83

    CAS  Google Scholar 

  7. Kochetkova VA, Mamontov AS, Moskovtseva RL, et al. Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms. Sov Med 1989; 6: 23–6

    PubMed  Google Scholar 

  8. Sakandelidze VV, Meipariani AN. Use of combined phages in suppurative-inflammatory diseases. Zh Mikrobiol Epidemiol Immunobiol 1974; 6:135–6

    Google Scholar 

  9. Litvinova AM, Chtesova VM, Kavtreva IG. Evaluation of efficacy of the use of E. coli-Proteus bacteriophage in intestinal dysbacteriosis in premature infants. Vopr Okhr Materin Det 1978; 9: 42–4

    Google Scholar 

  10. Solodovnikow IP, Pavlova LI, Emelyanov PI, et al. Prophylactic application of dry polyvalent dysentery bacteriophage with pectin in children’s preschool. I. Results of a strictly controlled epidemiologic trial (Yaroslavl, 1968). Zh Mikrobiol Epidemiol Immunobiol 1970; 47: 131–7

    Google Scholar 

  11. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307–18

    PubMed  CAS  Google Scholar 

  12. Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Microbiol 1987; 133 (Pt 5): 1127–35

    PubMed  CAS  Google Scholar 

  13. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987; 133 (Pt 5): 1111–26

    PubMed  CAS  Google Scholar 

  14. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129 (Pt 8): 2659–75

    PubMed  CAS  Google Scholar 

  15. Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 1998; 5(3): 294–8

    PubMed  CAS  Google Scholar 

  16. Berchieri A, Lovell MA, Barrow PA. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res Microbiol 1991; 142(5): 541–9

    PubMed  Article  Google Scholar 

  17. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 1992; 37(4): 258–61

    PubMed  Article  CAS  Google Scholar 

  18. Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20(3): 209–11

    PubMed  Article  CAS  Google Scholar 

  19. Strom MS, Paranjpye RN. Epidemiology and pathogenesis of Vibrio vulnificus. Microbes Infect 2000; 2: 177–88

    PubMed  Article  CAS  Google Scholar 

  20. Starks AM, Schoeb TR, Tamplin ML, et al. Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron dextran-treated mice. Infect Immun 2000; 68: 5785–93

    PubMed  Article  CAS  Google Scholar 

  21. Cerveny KE, Doyle TJ, Escudero GM, et al. Use of bacteriophage as therapy for disease caused by Vibrio vulnificus in iron dextran-treated mice [abstract no. D230]. American Society for Microbiology 100th General Meeting; 2000 May 21–25; Los Angeles (CA): 279

  22. Park SC, Shimamura I, Fukunaga M, et al. Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol 2000; 66(4): 1416–22

    PubMed  Article  CAS  Google Scholar 

  23. Flaherty JE, Jones JB, Harbaugh BK, et al. Control of bacterial spot on tomato in the greenhouse and field with H-mutant bacteriophages. HortScience 2000; 35: 882–4

    Google Scholar 

  24. DePaola A, Gulig PA, Smith JG, et al. Use of bacteriophage for elimination of Vibrio vulnificus from oysters [abstract no. P67]. American Society for Microbiology 101st General Meeting; 2001 May 20–24; Orlando (FL): 570

  25. Bogovazova GG, Voroshilova NN, Bondarenko VM, et al. Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh Mikrobiol Epidemiol Immunobiol 1992; 3: 30–3

    PubMed  Google Scholar 

  26. Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 1996; 93: 3188–92

    PubMed  Article  CAS  Google Scholar 

  27. Schaechter M, Engleberg NC, Eisenstein BI, et al. editors. Mechanisms of microbial disease. 2nd ed. Baltimore: Williams and Wilkins, 1998

    Google Scholar 

Download references


Our studies of phage therapy have been supported by funds from a Johnson and Johnson, Inc. Focused Giving Award and National Oceanographic and Atmospheric Administration SeaGrant GMO-99-1.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Paul A. Gulig.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Duckworth, D.H., Gulig, P.A. Bacteriophages. BioDrugs 16, 57–62 (2002).

Download citation

  • Published:

  • Issue Date:

  • DOI:


  • Dysentery
  • Bacillary Dysentery
  • Staphylococcal Infection
  • Phage Therapy
  • Antibacterial Resistance